This medicine is authorised for use in the European Union.


Forxiga is a medicine used to treat adults with diabetes, heart failure and chronic (long-term) kidney disease.

In diabetes, the medicine is used in adults whose condition is not controlled well enough.

• In type 2 diabetes, it is used with appropriate diet and exercise in patients who cannot take metformin (another diabetes medicine). It can also be used as ‘add-on’ treatment to other diabetes medicines.

• In type 1 diabetes, Forxiga is used with insulin in overweight patients (body mass index of at least 27 kg/m2) when insulin on its own does not control blood sugar well enough.

In heart failure, Forxiga is used in adults who have symptoms of the disease and reduced ejection fraction (a measure of how well the heart pumps blood). Heart failure is the inability of the heart to pump enough blood around the body.

In chronic kidney disease, Forxiga is used in adults with reduced kidney function.

Forxiga contains the active substance dapagliflozin.

This EPAR was last updated on 02/09/2021

Authorisation details

Product details
Agency product number
Active substance
dapagliflozin propanediol monohydrate
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus, Type 1
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
AstraZeneca AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address
151 85 Sodertalje

Product information

05/08/2021 Forxiga - EMEA/H/C/002322 - WS1941


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Type 2 diabetes mellitus
Forxiga is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
-- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Type 1 diabetes mellitus
Forxiga is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Heart failure
Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

Chronic kidney disease
Forxiga is indicated in adults for the treatment of chronic kidney disease.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
4 ratings
1 rating
1 rating